AllOut Marketing to Provide Marketing and Creative Development Services To SurModics
St. Louis Park, Minn. (November 20, 2008) – SurModics, Inc. selects AllOut Marketing, Inc. to provide marketing communications and web development services for its In Vitro Technologies business. SurModics’ In Vitro Technologies business develops innovative diagnostic assay components and technologies that serve the in vitro diagnostic, biopharmaceutical, and research markets.
“Our In Vitro Technologies business is growing and expanding rapidly. With growth comes the need to focus our message and communicate clearly the depth and breadth of our products to our expanded market,” said Doug Astry, General Manager In Vitro Technologies. “AllOut Marketing brings extensive experience in the life sciences, specifically in in vitro diagnostics.”
“We are honored that SurModics chose AllOut Marketing to heighten the awareness of their In Vitro Technologies business and products. We know this market extremely well and look forward to developing targeted, effective strategies and communications for SurModics,” said Ruth Lane, president and CEO of AllOut Marketing.
AllOut Marketing, Inc. serves the medical, bioscience, and pharmaceutical sectors, offering highly specialized medical marketing consulting, graphic design, web development, event management, public relations and market research. It is a full service strategic marketing and creative development firm with expertise ranging from strategy development to tactical implementation. Visit the AllOut Marketing website for more information.
SurModics, Inc. is a leading provider of surface modification and drug delivery technologies to the healthcare industry. SurModics partners with the world’s foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved patient outcomes. Core offerings include: drug delivery technologies (coatings, microparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. Collaborative efforts include a sustained drug delivery system in human trials for treatment of retinal disease and the drug delivery polymer matrix on the first-to-market drug-eluting coronary stent.
SurModics is headquartered in Eden Prairie, Minnesota and its Brookwood Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more information about the company, visit the SurModics website.
— Posted 11/20/2008
